Welsh firm announces stem cell logistics joint venture

1 Oct 2013
Kerry Parker
CEO

Industry news

Biotec Services International, a leader in clinical trials supply chain management, has announced a joint venture with AwenID, a Swansea University Life Sciences spin-out company, to develop technology that increases efficiency and reduces risk in stem cell therapies.

The new joint venture company, TrakCel, will develop tracking technology for the full lifecycle of stem cell-based therapies, to help ensure that patients receive the correct treatment at the right time and location.

Efficient and controlled delivery of stem cells is critical as they have a very short life span and need to be transported, manufactured and re-introduced to patients in a safe, controlled and scalable way.

TrakCel’s technology will also provide physicians with the ability to track the movements and temperatures of cell-based therapies and ensure the cells have the best opportunity of being successfully re-introduced to patients.

Keren Winmill, chief executive officer of Biotec Services International, said: “We’re committed to leading the world in supply chain management. The technology and solutions we envisage for the future will be made possible through innovation and focus at TrakCel.”

The Joint Venture has been supported by the Welsh Government Research, Innovation and Development Grant.

AwenID brings its patent pool and significant expertise in designing, developing and integrating identification, automation and tracking technologies including Biometrics, RFID, AutoID, GPS, GPRS, 4G and wireless technologies to the partnership.

Kevin Smith, a director of AwenID, and newly-appointed chief executive officer of the joint venture, said: “We’re all hugely excited at the opportunities that lie ahead for TrakCel. Biotec’s heritage in clinical trial supply chain management allied to AwenID’s proven capability and patent-pool in automation and tracking, will solve some key challenges for the nascent cell therapy industry as it begins to scale-up and scale-out globally.”

Management structure and a senior design team are currently in place for TrakCel, with the company planning to announce progress of technology development in the autumn of 2013.

Tags

Cell Lines Stem Cells and Primary CellsPrimary cell cultures, established cell lines and stem cells are vital for <i>in vitro</i> and <i>ex vivo</i> experimentation. High-quality cells, optimized for your applications, alongside optimized cell substrates, growth medium and supplements, are critical for experimental success. Explore a range of cells suitable for your applications, including isogenic cell lines, competent cells, induced pluripotent stem cell (iPSC)-derived cell lines, fungal/bacterial/mammalian cell lines, stem cells and cancer cell lines. Find the best cells for your research in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.Stem Cell ResearchStem cells have the ability to produce identical daughter cells as well as progeny, which commit and differentiate. Stem cell research has exciting prospects of biomedical applications in cellular disease modeling, pharmaceutical screening, and regenerative medicine. Collaboration